- Home
- MTEK vs TOVX Comparison
MTEK vs TOVX Comparison
Compare MTEK & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTEK | TOVX |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 11.1M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MTEK | TOVX |
|---|---|---|
| Price | $0.76 | $0.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | ★ 377.0K | 326.6K |
| Earning Date | 09-02-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $0.16 |
| 52 Week High | $2.82 | $0.86 |
Technical Indicators
Market Signals| Indicator | MTEK | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 24.26 | 46.15 |
| Support Level | N/A | $0.22 |
| Resistance Level | $1.34 | $0.26 |
| Average True Range (ATR) | 0.07 | 0.01 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 1.58 | 44.13 |
Price Performance
Historical ComparisonAbout MTEK Maris-Tech Ltd.
Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.